Abstract
Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors after conventional treatment. The advent of selective cell culture protocols for the propagation of patient-derived glioma stem-like cells (GSCs) provides researchers the ability to selectively study the cells that could be at the root of tumor proliferation and resistance to therapy. As these techniques are widely applied in contemporary studies and becoming the preferred in vitro model, molecular characterization of GSCs is considered pivotal for the identification and advancement of novel therapies for this devastating disease.
This review aims to provide an overview of canonical molecular alterations defining subtypes of malignant glioma as derived from genotypic, transcriptomic and epigenetic profiling in relation to their representation in GSC models. The distribution of these hallmark alterations as found in characterization studies of GSCs is compared between publications. Finally, conclusions of these studies with respect to coverage of driving alterations and translational relevance are provided. By doing so, we provide a contemporary overview of scientific results derived from GSC models and hopefully create appreciation of the advantages and caveats of utilizing these models for studying malignant glioma.Keywords: Glioblastoma, in vitro models, GSC, tumor profiling, TCGA, cell culture, tumor heterogeneity.
Current Cancer Drug Targets
Title:Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Volume: 17 Issue: 3
Author(s): Rutger K. Balvers, Clemens M.F. Dirven, Sieger Leenstra and Martine L.M. Lamfers
Affiliation:
Keywords: Glioblastoma, in vitro models, GSC, tumor profiling, TCGA, cell culture, tumor heterogeneity.
Abstract: Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors after conventional treatment. The advent of selective cell culture protocols for the propagation of patient-derived glioma stem-like cells (GSCs) provides researchers the ability to selectively study the cells that could be at the root of tumor proliferation and resistance to therapy. As these techniques are widely applied in contemporary studies and becoming the preferred in vitro model, molecular characterization of GSCs is considered pivotal for the identification and advancement of novel therapies for this devastating disease.
This review aims to provide an overview of canonical molecular alterations defining subtypes of malignant glioma as derived from genotypic, transcriptomic and epigenetic profiling in relation to their representation in GSC models. The distribution of these hallmark alterations as found in characterization studies of GSCs is compared between publications. Finally, conclusions of these studies with respect to coverage of driving alterations and translational relevance are provided. By doing so, we provide a contemporary overview of scientific results derived from GSC models and hopefully create appreciation of the advantages and caveats of utilizing these models for studying malignant glioma.Export Options
About this article
Cite this article as:
Balvers K. Rutger, Dirven M.F. Clemens, Leenstra Sieger and Lamfers L.M. Martine, Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813191809
DOI https://dx.doi.org/10.2174/1568009616666160813191809 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy The Hedgehog Knows Many Tricks
Current Drug Targets Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Current Pharmaceutical Design Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Marine Natural Products with High Anticancer Activities
Current Medicinal Chemistry Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery)
Current Pharmaceutical Design Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry In Vivo Application and Tracking of Baculovirus
Current Gene Therapy A Closer Look at α-Secretase
Current Alzheimer Research Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Multicomponent 1,3-Dipolar Cycloaddition Reactions in the Construction of Hybrid Spiroheterocycles
Current Organic Chemistry Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?
Current Angiogenesis (Discontinued) Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry